ERBB2 and breast carcinoma: It could be of interest to investigate whether dual inhibition of HER2 with trastuzumab and lapatinib is associated with a more effective eradication of both HER2-positive and p95HER2-positive CTCs, in order to provide an explanation for the increased clinical efficacy of this combination in HER2-positive breast cancer patients.